{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:38:29Z","timestamp":1774456709857,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:p>This commentary focuses on the article by Correa et al on the association of circulating tumor DNA with patient prognosis in renal cell carcinoma.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae230","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:49:49Z","timestamp":1724719789000},"page":"821-823","source":"Crossref","is-referenced-by-count":9,"title":["Liquid biopsy in renal cell carcinoma"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5695","authenticated-orcid":false,"given":"Marc","family":"Eid","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2315-8422","authenticated-orcid":false,"given":"Karl","family":"Semaan","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3424-6585","authenticated-orcid":false,"given":"Razane","family":"El Hajj Chehade","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-5660","authenticated-orcid":false,"given":"Rashad","family":"Nawfal","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4087-8606","authenticated-orcid":false,"given":"Sylvan C","family":"Baca","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"4","key":"2024100317301317100_CIT0001","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"2024100317301317100_CIT0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/cas.13906","article-title":"Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma","volume":"110","author":"Yamamoto","year":"2019","journal-title":"Cancer Sci."},{"key":"2024100317301317100_CIT0003","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.12659\/MSM.902077","article-title":"Aberrant promoter methylation of PCDH17 (Protocadherin 17) in serum and its clinical significance in renal cell carcinoma","volume":"23","author":"Lin","year":"2017","journal-title":"Med Sci Monit"},{"key":"2024100317301317100_CIT0004","first-page":"oyae180","article-title":"Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma","author":"Correa","year":"2024","journal-title":"Oncologist."},{"issue":"1","key":"2024100317301317100_CIT0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13073-020-00723-8","article-title":"Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors","volume":"12","author":"Smith","year":"2020","journal-title":"Genome Med."},{"issue":"1","key":"2024100317301317100_CIT0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/KCA-170007","article-title":"Association of Circulating Tumor DNA (ctDNA) detection in Metastatic Renal Cell Carcinoma (mRCC) with tumor burden","volume":"1","author":"Maia","year":"2017","journal-title":"Kidney Cancer"},{"issue":"4","key":"2024100317301317100_CIT0007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","article-title":"Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma","volume":"72","author":"Pal","year":"2017","journal-title":"Eur Urol."},{"issue":"4","key":"2024100317301317100_CIT0008","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clgc.2019.12.018","article-title":"Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma","volume":"18","author":"Bacon","year":"2020","journal-title":"Clin Genitourin Cancer."},{"issue":"17","key":"2024100317301317100_CIT0009","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-21-0572","article-title":"Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma","volume":"27","author":"Zengin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024100317301317100_CIT0010","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41436-020-0801-x","article-title":"Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma","volume":"22","author":"Lasseter","year":"2020","journal-title":"Genet Med."},{"issue":"7","key":"2024100317301317100_CIT0011","doi-asserted-by":"crossref","first-page":"e2300131","DOI":"10.1200\/PO.23.00131","article-title":"Longitudinal monitoring of circulating tumor DNA to assess the efficacy of immune checkpoint inhibitors in patients with advanced genitourinary malignancies","volume":"7","author":"Jang","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"2024100317301317100_CIT0012","doi-asserted-by":"crossref","first-page":"e2200543","DOI":"10.1200\/PO.22.00543","article-title":"Ultrasensitive circulating tumor DNA pilot study distinguishes complete response and partial response with immunotherapy in patients with metastatic renal cell carcinoma","volume":"7","author":"Chehrazi-Raffle","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"29","key":"2024100317301317100_CIT0013","doi-asserted-by":"crossref","first-page":"20467","DOI":"10.18632\/oncotarget.24943","article-title":"Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma","volume":"9","author":"Yamamoto","year":"2018","journal-title":"Oncotarget"},{"issue":"4_suppl","key":"2024100317301317100_CIT0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2024.42.4_suppl.199","article-title":"Fragmentomics of cell-free DNA from targeted panels in genitourinary malignancies","volume":"42","author":"Taylor","year":"2024","journal-title":"J Clin Oncol."},{"issue":"7","key":"2024100317301317100_CIT0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med."},{"issue":"11","key":"2024100317301317100_CIT0016","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat Med."},{"issue":"6","key":"2024100317301317100_CIT0017","doi-asserted-by":"crossref","first-page":"114350","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"Zarif","year":"2024","journal-title":"Cell Rep"},{"key":"2024100317301317100_CIT0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13148-018-0444-9","article-title":"Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma","volume":"10","author":"Heinemann","year":"2018","journal-title":"Clin Epigenetics"},{"key":"2024100317301317100_CIT0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clinbiochem.2019.10.002","article-title":"Prognostic urinary miRNAs for the assessment of small renal masses","volume":"75","author":"Di Meo","year":"2020","journal-title":"Clin Biochem."},{"issue":"1","key":"2024100317301317100_CIT0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12032-016-0875-0","article-title":"CTC clusters in cancer progression and metastasis","volume":"34","author":"Fabisiewicz","year":"2017","journal-title":"Med Oncol."},{"issue":"10","key":"2024100317301317100_CIT0021","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/cells8101145","article-title":"CTC-derived models: a window into the seeding capacity of Circulating Tumor Cells (CTCs)","volume":"8","author":"Tayoun","year":"2019","journal-title":"Cells"},{"issue":"9","key":"2024100317301317100_CIT0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/onco.13842","article-title":"Prognostic role of circulating tumor cells in metastatic renal cell carcinoma: a large, multicenter, prospective trial","volume":"26","author":"Basso","year":"2021","journal-title":"Oncologist."},{"issue":"4","key":"2024100317301317100_CIT0023","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/15384047.2018.1538000","article-title":"Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies","volume":"20","author":"Ye","year":"2018","journal-title":"Cancer Biol Ther."},{"issue":"16_suppl","key":"2024100317301317100_CIT0024","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","article-title":"Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: a randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection","volume":"42","author":"Albiges","year":"2024","journal-title":"J Clin Oncol."},{"issue":"15","key":"2024100317301317100_CIT0025","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant Pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med."},{"issue":"1","key":"2024100317301317100_CIT0026","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med."},{"issue":"7867","key":"2024100317301317100_CIT0027","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae230\/59558445\/oyae230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae230\/59558445\/oyae230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:35:26Z","timestamp":1727976926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/821\/7742171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,26]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae230","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,26]]}}}